NeoLight makes hospital‑grade phototherapy hardware intended to treat neonatal jaundice, a condition affecting roughly 60% of newborns. The company originally designed its devices for hospital use but pivoted to market the hardware to new parents. The pivot responds to trends toward earlier newborn discharge and home quarantine, when doctors may not know if treatment is necessary until three or four days after birth. NeoLight’s therapies aim to offer clinical-grade treatment at home to prevent bilirubin-related brain damage. Founder Vivek Kopparthi has described the timing gap between discharge and detection of treatment need as a core challenge the product addresses. The company recently secured additional financing to support this consumer-facing push.

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2020